

# Healthpeak® | DOC NYSE



# **Investor Presentation**

November 18, 2024

## **Disclaimers**

This Healthpeak Properties, Inc. (the "Company") presentation is solely for your information, is subject to change and speaks only as of the date hereof. This presentation is not complete and is only a summary of the more detailed information included elsewhere, including in our Securities and Exchange Commission ("SEC") filings. No representation or warranty, express or implied, is made and you should not place undue reliance on the accuracy, fairness or completeness of the information presented.

#### Forward-Looking Statements

Statements contained in this presentation that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof.

Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release, including statements regarding our anticipated synergies from our merger with Physicians Realty Trust (the "Merger"); (ii) information presented under the heading "Current 2024 Guidance" and outlooks relating to lab and outpatient medical; and (iii) potential capital sources and uses. Pending acquisitions, dispositions, development or redevelopment activity, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends. including inflation, interest rates, construction and labor costs, and unemployment; risks associated with the merger, including, but not limited to, our ability to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Merger or do so within the anticipated time frame; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants', operators', or borrowers' ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, including project abandonments, project

delays, and lower profits than expected; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third-party management contracts, including the additional regulation and liabilities of our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as "RIDEA"); economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our use of joint ventures that may limit our returns on and our flexibility with jointly owned investments; our use of fixed rent escalators, contingent rent provisions, and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; our ability to satisfy environmental, social and governance and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including the coronavirus disease (Covid), and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology systems and any material failure, inadequacy, interruption, or security failure of that technology; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, including due to rising interest rates; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, bank failures or other events affecting financial institutions and other factors; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services: our participation in the Coronavirus, Aid, Relief and Economic Security Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a real estate investment trust ("REIT"); our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from "prohibited transactions"; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may

otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC ("Healthpeak OP") common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings.

Moreover, other risks and uncertainties of which we are not currently aware may also affect our forward-looking statements, and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We do not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

#### Market and Industry Data

This presentation also includes market and industry data that the Company has obtained from market research, publicly available information and industry publications. The accuracy and completeness of such information are not guaranteed. Such data is often based on industry surveys and preparers' experience in the industry. Similarly, although Healthpeak believes that the surveys and market research that others have performed are reliable, such surveys and market research are subject to assumptions, estimates and other uncertainties and Healthpeak has not independently verified this information.

#### Non-GAAP Financial Measures

This presentation contains certain supplemental non-GAAP financial measures. While the Company believes that non-GAAP financial measures are helpful in evaluating its operating performance, the use of non-GAAP financial measures in this presentation should not be considered in isolation from, or as an alternative for, a measure of financial or operating performance as defined by GAAP. We caution you that there are inherent limitations associated with the use of each of these supplemental non-GAAP financial measures as an analytical tool. Additionally, the Company's computation of non-GAAP financial measures may not be comparable to those reported by other REITs. You can find reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures in the third quarter 2024 Discussion and Reconciliation of Non-GAAP Financial Measures available on our website at http://ir.healthpeak.com/guarterly-results. This document is hereafter referred to as the "3Q24 Non-GAAP" in these materials. In addition, the Appendix to this presentation entitled "Reconciliation of Certain Non-GAAP Financial Measures" provides updated reconciliations for certain forward-looking non-GAAP financial measures to their respective most directly comparable GAAP financial measure. These updated reconciliations supersede pages 9-11 of the Discussion and Reconciliation of the 3Q24 Non-GAAP. Other than the updates described herein and set forth below, the 3Q24 Non-GAAP remains unchanged. Definitions and a discussion of non-GAAP financial measures presented herein are included in the 3Q24 Non-GAAP.



## **About Healthpeak**

Healthpeak is a leading owner, operator, and developer of real estate for healthcare discovery and delivery. Our real estate is uniquely positioned to benefit from the aging population and universal desire for better health with purpose-built lab campuses and a high-quality outpatient medical portfolio affiliated with leading health systems.


49M SF 700 Properties

\$24B **Total Assets** 

5.8% **Dividend Yield**  Baa1 / BBB+ **Credit Rating** 

**S&P 500** Company







## Why Invest in Healthpeak

Compelling
Value and
Growth
Opportunity<sup>(1)</sup>


- Well-covered ~5.8% dividend yield + 4.5% same-store growth
- \$60M future Cash NOI upside from marquee lab dev/redev campuses plus at least \$10M additional merger synergies in 2025+
- Under-levered balance sheet with \$500M to \$1B of dry powder for accretive investments
- Additional total return opportunity from stock price reversion to consensus NAV and historical FFO multiple


Executing
With
Excellence<sup>(1)</sup>

- Double digit earnings growth over the last three years (FFO as Adjusted +12% | AFFO +17%)
- Increased midpoints of 2024 guidance for FFO as Adjusted and AFFO by +5 pennies and same-store growth by +150 basis points vs original 2024 guidance
- Merger synergies tracking to \$50M in 2024; outperformance driven by property management internalization
- YTD dispositions of \$1.2B at a 6.5% cap rate; \$188M of share repurchases at a high-7% implied cap rate
- YTD executed 1.7M SF of lab leases and 5.3M SF of outpatient medical leases

# Under-Levered Balance Sheet with \$500M to \$1B of Dry Powder for Accretive Investments

Well-laddered maturities and BBB+ / Baa1 (stable) credit rating







## **Double Digit Earnings Growth Over the Past Three Years**

Earnings growth driven by development earn-in, property performance, merger synergies, and more efficient G&A

FFO as Adjusted per Share<sup>(1)</sup>







# **Increased Earnings Guidance 4 Times in 2024**


	Original 2024 Guidance <sup>(1)</sup>	Current 2024 Guidance	Midpoint Variance
FFO as Adjusted	\$1.76	\$1.81	+ \$0.05
AFFO	\$1.53	\$1.58	+ \$0.05
Same-Store Growth	3.0%	4.50%	+ 150 bps

# Executed Leases to Capture >50% of \$60M Cash NOI Upside from Marquee Development and Redevelopment Campuses

	Potential Upside 2025+ NOI <sup>(1)</sup>	Leased / Committed Upside 2025+ NOI	% Upside Leased or Committed <sup>(2)</sup>	Recent Updates <sup>(3)</sup>
Portside Redevelopment	+\$25M	+\$19M	~75%	■ In October, signed a 205K SF lease with an existing private life science tenant
Vantage Development	+\$15M	+\$7M	~50%	■ In October, signed a 63K SF lease with an existing private biotech tenant
Gateway Development	+\$10M	+\$5M	~50%	■ In 3Q, signed a 37K SF lease with a private biotech tenant and a 33K SF letter of intent (LOI) with a mid-cap biotech
Directors Place Redevelopment	+\$10M	+\$2M	~20%	In October, signed a 33K SF LOI with an existing private biotech tenant
	+\$60M	+\$33M	> 50%	

## **Outperforming Merger Synergy Targets**

Accelerated internalization and higher profit margins resulted in +\$10 million of additional earnings benefit during 2024



## **Property Management Internalization Update**

Market	SF (M)	Completion
Bay Area	6.2	Feb 2024
San Diego	2.2	Feb 2024
Dallas	2.0	Mar 2024
Nashville	1.8	Apr 2024
Louisville	1.5	Apr 2024
Seattle	0.8	Apr 2024
Chicago	0.6	Apr 2024
Indianapolis	0.3	Apr 2024
Wisconsin	0.2	Apr 2024
Arkansas	0.5	May 2024
Arizona	1.1	Jul 2024
Mississippi	0.2	Jul 2024
Denver	1.2	Sep 2024
Utah	0.8	Sep 2024
Year-to-Date Total	19.4	
Additional Markets in 2025+	~14	
Previously Internalized	~5	
Total	~38	DOC 75+% internally managed upon completion

# **Lab Overview**

## We Continue to Outperform

**Year to Date Results:** 

1.7M SF of Leasing

+7% Cash Rent MTM

96% Occupancy

## **Tenant Priority Checklist**

## **Healthpeak Competitive Advantage**

**Prime Locations** 

 $\bigcirc$ 

Exclusively located in top markets / submarkets: ~70% of ABR in South San Francisco, Torrey Pines, and Cambridge

Brand Name and Reputation



Industry leader for 20+ years partnering with leading biopharma tenants

High-Quality Portfolio



Purpose-built product at a range of price points and suite sizes to cater to diverse tenant requirements; ~85% of ABR from campuses 400K+ SF

Scale and Expertise



11M SF portfolio with strategic land bank to fulfill tenant growth needs

Established Industry Relationships



200 existing tenant relationships overseen by best-in-class local teams in Bay Area, Boston, and San Diego markets

Capitalization and Stability



Long-term owner with unencumbered BBB+ / Baa1 rated balance sheet provides comfort for tenants

## Strategically Located in Long-Established Life Science Submarkets

Well-occupied portfolio with upside from lease-up of South San Francisco and Sorrento Mesa re/developments

Lab Market <sup>(1)</sup>	Submarkets	Percent of Total Healthpeak ABR	Total SF	Occupancy Operating   Total <sup>(2)</sup>
	South San Francisco	19.4%	5,030K	95%   83%
Bay Area	Redwood City	2.9%	645K	96%   96%
	Hayward	1.5%	530K	99%   99%
Doctor	West Cambridge	5.3%	1,430K	92%   92%
Boston	Lexington / Waltham	5.0%	1,315K	100%   100%
	Torrey Pines	3.6%	1,160K	93%   91%
San Diego	Sorrento Mesa	1.6%	900K	100%   75%
	UTC	0.4%	135K	89%   89%
Total Healthpeak		39.7%	11.1M	96%   88%



Square footage includes operating portfolio and expected square footage from development and redevelopment properties. Percent of 3Q 2024 Annualized Base Rent (ABR) based on operating Investor Presentation – November 2024

## Platform and Footprint to Drive Leasing and Capture Market Share

## **Key Healthpeak Statistics**

~200 Existing Tenants

75% of 2024 Lease **Executions with Existing Tenants** 


83% TTM Tenant Retention<sup>(1)</sup>

#### **Select 2024 Lease Executions**

Existing Tenant	Quarter Signed	Campus	Tenant Type	Tenant Total SF	SF Increase
	4Q	Portside	Private Life Science	205,000	~150,000
	4Q	Vantage	Private Biotech	63,000	17,000
	3Q	Pointe Grand	Private Biotech	51,000	51,000
	3Q	Seaport	Mid-Cap Biotech	186,000(2)	43,000
	3Q	Gateway	Private Biotech	37,000	37,000
	3Q	The Cove	Private Biotech	36,000	36,000
	2Q	Torrey Pines	Large-Cap Biopharma	86,000	21,000


# **Biotech Capital Markets Activity Has Increased Significantly**

Increased capital raising is having a direct and positive impact on Healthpeak's leasing activity



## **Healthpeak Leasing Activity Has Accelerated**

2024 leasing activity has increased significantly, Healthpeak is capturing market share, and the pipeline remains strong




## New Supply is Declining Precipitously with Essentially NO New Starts

The supply / demand environment is set up to improve significantly as we head into 2025+

#### Vacant / Non-Pre-Leased Lab Deliveries(1)


SF in millions

20M



## Limited 2025 & 2026 Lab Lease Maturities

The majority of 2025 leasing requirements are either under LOI, in active discussions, or are anticipated redevelopments




# Outpatient Medical Overview

## **Unmatched Outpatient Medical Portfolio & Platform**

## Best-in-class portfolio and platform differentiate Healthpeak

527 38M SF **Properties** 92% 5.6 Year Occupancy Remaining Lease Term **Leading Scale &** 89% +7.8% **Portfolio Quality** YTD Cash Re-Leasing Spreads TTM Retention Rate With Unmatched **Experience &** 96% 70% **Health System** On-Campus or Affiliated Leased to Health Systems Relationships Sector Leading Same-Store Growth<sup>(1)</sup> **Vertically Integrated Platform** 




## Superior Relationships with Leading Health Systems in Each Local Market

Broad and deep health system relationships create outsized opportunities for internal and external growth



#### Healthpeak Relationships Within Top 10 OM Markets<sup>(2)</sup>



## **Development & Loan Opportunities Create Pipeline for External Growth**

## Health system relationships provide proprietary opportunities for investment in trophy quality development assets



#### Northside Medical Buford Atlanta, GA

NORTHSIDE HOSPITAL

Delivered: 2Q 2024

Investment	\$38M
Size (SF)	97K
\$ / psf	\$392
% Pre-Leased	100%



#### Galen Aurora Denver, CO



Estimated: 2Q 2025

Investment	\$40M
Size (SF)	72K
\$ / psf	\$555
% Pre-Leased	100%



#### HonorHealth Pima (Loan) Phoenix, AZ



Estimated: 4Q 2025

Investment	\$44M
Interest Rate	7.5%
Size (SF)	97K
% Pre-Leased	86%



#### Abrazo Buckeye (Loan) Phoenix, AZ




Estimated: 1Q 2025

Investment	\$21M
Interest Rate	9.4%
Size (SF)	63K
% Pre-Leased	90%

## **Favorable Sector Fundamentals**


## Supply and demand fundamentals provide favorable backdrop for accelerating growth in rent and NOI






Healthcare expenditures are increasing alongside the aging of America...

#### **OM Construction Cost PSF**




Inflation has increased the replacement cost of Outpatient Real Estate...

#### **Growth of Visits by Insured Patients** (1Q18 Baseline)



... with care delivery migrating to outpatient settings due to lower cost and consumer preference.

#### **OM Construction Starts (SF)**





... reducing construction starts and increasing demand for existing facilities.


## **Recent Dispositions Enhance Portfolio Quality**

## Sale of 72 non-core assets for \$876M fortifies Healthpeak's leading OM portfolio


Improved Portfolio Quality














**Expected Population Growth Rate** 

Market	Sale #	% Sale SF
Ohio (Columbus & Cincinnati)	13	23%
<b>Nebraska</b> (Omaha & Grand Island)	7	16%
North Dakota (Bismarck, Minot, Williston)	7	12%
New York (Syracuse & Rochester)	7	11%

**Disposition Portfolio Markets** 

## CommonSpirit Renewal Exceeded Street Expectations

#### **Discussion**

- In July 2024, Healthpeak executed an early lease renewal with CommonSpirit, extending the entirety of the Company's 2M square foot relationship
- □ Prior to this extension, 80% of related leases were due to expire in 2026, 2027, and 2028
- This renewal exemplifies DOC's focus on the cultivation of long-term relationships with leading health systems
- □ Added +8 years of lease term, increasing in-place WALT to +11 years
- □ Achieved +13% blended cash re-leasing spread
- □ Annual escalator increased from 2.5% to 3.0%



#### **Lease KPIs & Maturity Schedule**

2M SF

Renewed Square Footage

+13%

Cash Re-Leasing Spread

+8.2 Years

Lease Term Added +3.0%

New Annual Escalator



# Appendix: Reconciliation of Certain Non-GAAP Financial Measures

## 2024 Current Guidance Reconciliation<sup>(1)</sup>

On November 18, 2024, Healthpeak Properties, Inc. (the "Company") increased its full year 2024 guidance ranges for diluted earnings per common share, diluted Nareit FFO per common share, diluted FFO as Adjusted per common share, diluted AFFO per common share, Cash (Adjusted) NOI, and Merger-Combined Same-Store Cash (Adjusted) NOI. The Appendix provides updated reconciliations for these forward-looking non-GAAP financial measures to their respective most directly comparable GAAP financial measure. These updated reconciliations supersede pages 9-11 of the Discussion and Reconciliation of the 3Q24 Non-GAAP. Other than the updates described herein and set forth below, the 3Q24 Non-GAAP remain unchanged. Definitions and a discussion of non-GAAP financial measures presented herein are included in the 3Q24 Non-GAAP.

	2024 Guidance Ranges			
		Low		High
Diluted earnings per common share	\$	0.41	\$	0.43
Real estate related depreciation and amortization		1.55		1.55
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures		0.07		0.07
Noncontrolling interests' share of real estate related depreciation and amortization		(0.03)		(0.03)
Loss (gain) on sales of depreciable real estate, net		(0.28)		(0.28)
Loss (gain) upon change of control, net		(0.12)		(0.12)
Taxes associated with real estate dispositions		0.02		0.02
Diluted Nareit FFO per common share	\$	1.62	\$	1.64
Transaction and merger-related items	\$	0.16	\$	0.16
Other impairments (recoveries) and other losses (gains), net		0.02		0.02
Diluted FFO as Adjusted per common share	\$	1.80	\$	1.82
Stock-based compensation amortization expense	\$	0.03	\$	0.03
Amortization of deferred financing costs and debt discounts (premiums)		0.05		0.05
Straight-line rents		(0.07)		(0.07)
AFFO capital expenditures		(0.18)		(0.18)
Amortization of above (below) market lease intangibles, net		(0.05)		(0.05)
Other AFFO adjustments		(0.01)		(0.01)
Diluted AFFO per common share	\$	1.57	\$	1.59

## 2024 Current Guidance Reconciliation<sup>(1)</sup>

For the projected year 2024	Total Portfolio			
Net Income	\$	301	\$	315
Real estate related depreciation and amortization		1,050		1,050
Loss (gain) on sales of depreciable real estate, net		(188)		(188)
Other impairments (recoveries) and other losses (gains), net		11		11
Other income, costs, and expense adjustments for Cash (Adjusted) NOI		314		314
Cash (Adjusted) NOI	\$	1,488	\$	1,502
Pre-Merger legacy Physicians Realty Trust Adjusted NOI		53		53
Merger-Combined non-SS Adjusted NOI		(183)		(184)
Total Merger-Combined Same-Store Cash (Adjusted) NOI <sup>(2)</sup>	\$	1,358	\$	1,371

For the year-ended December 31, 2023	Total Portfolio	
Net Income	\$	335
Real estate related depreciation and amortization		750
Loss (gain) on sales of depreciable real estate, net		(86)
Other impairments (recoveries) and other losses (gains), net		(6)
Other income, costs, and expense adjustments for Cash (Adjusted) NOI		212
Cash (Adjusted) NOI	\$	1,205
Pre-Merger legacy Physicians Realty Trust Adjusted NOI		312
Merger-Combined non-SS Adjusted NOI		(212)
Total Merger-Combined Same-Store Cash (Adjusted) NOI <sup>(2)</sup>	\$	1,305

#### Projected Merger-Combined Cash Same-Store for the full year 2024

Low	4.00%
High	5.00%

<sup>1)</sup> The foregoing projections reflect management's view of current and future market conditions as of November 18, 2024, including assumptions with respect to rental rates, occupancy levels, development items, and the earnings impact of the events referenced in our earnings press release that was issued on October 24, 2024. However, these projections do not reflect the impact of unannounced future transactions, except as described herein. Our actual results may differ materially from the projections set forth above. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments. May not foot or recalculate due to the rounding



# Healthpeak® | DOC NYSE